Sysmex Corporation (SSMXF)
OTCMKTS
· Delayed Price · Currency is USD
18.60
+2.80 (17.72%)
Mar 7, 2025, 4:00 PM EST
Sysmex Revenue
Sysmex had revenue of 124.39B JPY in the quarter ending December 31, 2024, with 9.28% growth. This brings the company's revenue in the last twelve months to 501.85B, up 14.50% year-over-year. In the fiscal year ending March 31, 2024, Sysmex had annual revenue of 461.51B with 12.43% growth.
Revenue (ttm)
501.85B JPY
Revenue Growth
+14.50%
P/S Ratio
n/a
Revenue / Employee
49.98M JPY
Employees
10,042
Market Cap
11.44B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 461.51B | 51.01B | 12.43% |
| Mar 31, 2023 | 410.50B | 46.72B | 12.84% |
| Mar 31, 2022 | 363.78B | 58.71B | 19.24% |
| Mar 31, 2021 | 305.07B | 3.09B | 1.02% |
| Mar 31, 2020 | 301.98B | 8.47B | 2.89% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 43.26M |
| BioStem Technologies | 210.49M |
Sysmex News
- 4 weeks ago - Sysmex reports 9M results - Seeking Alpha
- 4 months ago - Sysmex GAAP EPS of ¥41.70, revenue of ¥242.48B - Seeking Alpha